Tin tức & Cập nhật
Xem bài viết Tiêu hóa
Xem
Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.
Pembrolizumab plus lenvatinib effective against nonclear cell RCC
Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.
Contraceptives ease IBD symptoms but induce intestinal inflammation in women
Women with inflammatory bowel disease (IBD) who use hormonal contraceptives (HCs) appear to be less likely to experience IBD-related symptoms but are more likely to have intestinal inflammation over a year, reports a study.
Methylnaltrexone proves safety in paediatric oncology patients with constipation
Subcutaneous methylnaltrexone is safe to use in children with cancer who have opioid-induced constipation, suggest the results of a study. In addition, this agent stimulates bowel movements in more than a third of paediatric patients.
Infliximab, vedolizumab similarly effective as 1L Tx for paediatric IBD
In a study presented at Crohn’s and Colitis Congress 2024, infliximab and vedolizumab were found to have similar effectiveness in achieving steroid-free clinical remission (SFCR) and biochemical remission (BR) at 12 months when used as first-line treatment for biologic-naïve paediatric patients with uncomplicated mild-to-moderately active inflammatory bowel disease (IBD).